Impact of Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil Therapy on Synchronous Early-Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer

IF 2.2 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2026-10-10 Epub Date: 2026-05-20 DOI:10.1002/hed.70326

Tatsuya Ito, Go Omura, Chihiro Fushimi, Toshihiko Sakai, Azusa Sakai, Kohtaro Eguchi, Takaaki Hayashi, Takane Watanabe, Akihisa Tanaka, Mitsuhiko Katoh, Hiroshi Imazeki, Shun Yamamoto, Yoshitaka Honma, Hideaki Takahashi, Ken Kato, Seiichi Yoshimoto

{"title":"Impact of Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil Therapy on Synchronous Early-Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer","authors":"Tatsuya Ito, Go Omura, Chihiro Fushimi, Toshihiko Sakai, Azusa Sakai, Kohtaro Eguchi, Takaaki Hayashi, Takane Watanabe, Akihisa Tanaka, Mitsuhiko Katoh, Hiroshi Imazeki, Shun Yamamoto, Yoshitaka Honma, Hideaki Takahashi, Ken Kato, Seiichi Yoshimoto","doi":"10.1002/hed.70326","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>To evaluate the therapeutic effect of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (NeoDCF), the standard treatment for stage IB–III esophageal squamous cell carcinoma (ESCC), against synchronous superficial pharyngeal squamous cell carcinoma (PSCC).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We retrospectively reviewed ESCC patients with synchronous early-stage PSCC who received NeoDCF. The primary endpoint was disease-specific survival (DSS) for PSCC. Secondary endpoints included overall survival (OS), local tumor response, and time to progression (TTP) of PSCC.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 786 patients with ESCC, 58 (7.4%) had synchronous early-stage PSCC. Local tumor response was complete disappearance in 33 (57%) patients, partial reduction in 24 (41%), and no change in 1 (2%). The 3-year DSS, OS, and TTP were 100%, 61%, and 78%, respectively. No significant difference was found between the Tis and T1/T2 groups (<i>p</i> = 0.67).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>NeoDCF demonstrated excellent efficacy against early-stage PSCC, supporting prioritization of ESCC treatment with timely local intervention for recurrent PSCC.</p>\n </section>\n </div>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":"48 11","pages":"3097-3102"},"PeriodicalIF":2.2000,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hed.70326","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

To evaluate the therapeutic effect of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (NeoDCF), the standard treatment for stage IB–III esophageal squamous cell carcinoma (ESCC), against synchronous superficial pharyngeal squamous cell carcinoma (PSCC).

Methods

We retrospectively reviewed ESCC patients with synchronous early-stage PSCC who received NeoDCF. The primary endpoint was disease-specific survival (DSS) for PSCC. Secondary endpoints included overall survival (OS), local tumor response, and time to progression (TTP) of PSCC.

Results

Among 786 patients with ESCC, 58 (7.4%) had synchronous early-stage PSCC. Local tumor response was complete disappearance in 33 (57%) patients, partial reduction in 24 (41%), and no change in 1 (2%). The 3-year DSS, OS, and TTP were 100%, 61%, and 78%, respectively. No significant difference was found between the Tis and T1/T2 groups (p = 0.67).

Conclusions

NeoDCF demonstrated excellent efficacy against early-stage PSCC, supporting prioritization of ESCC treatment with timely local intervention for recurrent PSCC.

查看原文本刊更多论文

多西紫杉醇、顺铂和5-氟尿嘧啶新辅助治疗对食管癌患者同步早期口咽/下咽癌的影响

背景：评价IB-III期食管鳞状细胞癌（ESCC）标准治疗新辅助多西他赛、顺铂和5-氟尿嘧啶（NeoDCF）对同步性咽部浅表鳞状细胞癌（PSCC）的治疗效果。方法：我们回顾性分析ESCC合并同步早期PSCC接受NeoDCF的患者。主要终点是PSCC的疾病特异性生存（DSS）。次要终点包括PSCC的总生存期（OS）、局部肿瘤反应和进展时间（TTP）。结果：786例ESCC患者中，58例（7.4%）伴有早期同步PSCC。局部肿瘤反应完全消失33例（57%），部分减轻24例（41%），无变化1例（2%）。3年DSS、OS、TTP分别为100%、61%、78%。Tis组与T1/T2组间无统计学差异（p = 0.67）。结论：NeoDCF对早期PSCC表现出优异的疗效，支持优先治疗ESCC，及时局部干预复发性PSCC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.